Profile | GDS2987 / GI_37549382-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 4.6 | 17 |
GSM215244 | HMVEC_vehicle_rep2 | ||
GSM215253 | HMVEC_vehicle_rep3 | 12.5 | 39 |
GSM215254 | HMVEC_atorvastatin_rep1 | ||
GSM215282 | HMVEC_atorvastatin_rep3 | 4.4 | 11 |
GSM215344 | HMVEC_atorvastatin_rep2 | 23 | 49 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | ||
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | ||
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | ||
GSM215294 | HMVEC_SLx2119_rep1 | ||
GSM215295 | HMVEC_SLx2119_rep2 | 3 | 6 |
GSM215296 | HMVEC_SLx2119_rep3 | 14.4 | 24 |
GSM215297 | PASMC_vehicle_rep1 | 45.3 | 56 |
GSM215298 | PASMC_vehicle_rep2 | 42.2 | 54 |
GSM215310 | PASMC_vehicle_rep3 | 42.4 | 55 |
GSM215311 | PASMC_atorvastatin_rep1 | 82.7 | 72 |
GSM215312 | PASMC_atorvastatin_rep2 | 39.8 | 53 |
GSM215313 | PASMC_atorvastatin_rep3 | 34.9 | 46 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 46.3 | 59 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 11.5 | 23 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 45.5 | 59 |
GSM215327 | PASMC_SLx2119_rep1 | 3.9 | 7 |
GSM215328 | PASMC_SLx2119_rep2 | 20.6 | 36 |
GSM215329 | PASMC_SLx2119_rep3 | 49 | 64 |
GSM215330 | Fibroblasts_vehicle_rep1 | 20.1 | 42 |
GSM215331 | Fibroblasts_vehicle_rep2 | 25.1 | 55 |
GSM215332 | Fibroblasts_vehicle_rep3 | 19.6 | 52 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 7.3 | 20 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 16.9 | 43 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 30.5 | 57 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 40 | 67 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 28.6 | 62 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 34.6 | 63 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 30.3 | 61 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 18.5 | 46 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 41.3 | 65 |